MRNA — Bearish (ASignal Rank 4/4)
ASignal's 10+ AI agent pipeline rates MRNA as Bearish with 85% confidence in the Healthcare sector.
AI Analysis Summary
Avoid Moderna (MRNA) due to severe financial distress, unsustainable leverage, and negative cash flow despite a speculative price forecast.
Investment Framework Assessment
Evaluated through three legendary investor frameworks:
- Warren Buffett (Value Investing): Grade D — 25/100
- Bill Ackman (Activist Investing): Grade D — 45/100
- Ray Dalio (Macro/Risk Parity): Grade C — 50/100
Consensus: Bearish
Price Intelligence
- Current price: $50.73
- Price target: $48.25 (-4.9%)
- Risk level: high
- Horizon: medium term
Quality Assessment
- Balance sheet: concerning
- Cash flow: poor
- Competitive moat: intangible assets
Peer Group Analysis
MRNA is in the “Cash Flow Weak” cluster alongside XEL, WRB, WEC, TRGP, SO (43 stocks total). 0 of 43 peers are currently bullish.